BioSense, Neovacs Agree €65M Deal for Therapeutic SLE Vaccine in China
biotech | February 21, 2017
BioSense negotiated an option to license Neovacs’ Phase II-stage IFNα-Kinoid therapeutic vaccine candidate for treating systemic lupus erythematosus (SLE) in China and selected territories. Under terms of the deal, Neovacs could receive up to €65 million (approximately $68.5 million) in up-front and milestone payments, not including any future sales royalties. The deal is the second signed by Neovacs for the IFNα-Kinoid candidate. During late 2015, the firm inked a strategic partnering agreement with Chong Kun Dang (CKD) Pharmaceuticals for the South Korean market.